Akari Therapeutics (NASDAQ:AKTX) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a report issued on Monday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Akari Therapeutics Stock Performance

NASDAQ AKTX opened at $0.93 on Monday. The stock’s 50-day simple moving average is $1.13 and its two-hundred day simple moving average is $1.87. Akari Therapeutics has a twelve month low of $0.85 and a twelve month high of $4.40.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.